Pharmaceuticals

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

* New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide * Strategy centers on broadening access to global capital and innovation through a plannedHong Kong initial public offering (IPO), and holding...

2025-10-29 23:15 2784

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agree...

2025-10-29 17:01 967

What Hebei Can Offer丨Biomedicine and Beyond

SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...

2025-10-29 15:23 1142

A Breakthrough in Color Measurement Is Coming: The HunterLab Agera L2

RESTON, Va., Oct. 29, 2025 /PRNewswire/ -- A breakthrough in color measurement is on the horizon. This November,HunterLab will unveil theAgera L2, the next generation in spectr...

2025-10-29 08:00 1098

Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering")...

2025-10-29 04:15 2168

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced...

2025-10-28 22:07 1186

SI GROUP OPENS NEW INNOVATION CENTER

State-of-the-art facility expands company's global research and development capabilities THE WOODLANDS, Texas, Oct. 28, 2025 /PRNewswire/ -- SI Group , a leading global developer and ...

2025-10-28 20:30 919

Fosun Pharma Announces 2025Q3 Financial Results

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs ExceedingRMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 60019...

2025-10-28 20:11 1876

Xinhua Silk Road: Innovation, tradition deeply integrated on TCM trade fair in China's Zhangshu City

BEIJING, Oct. 28, 2025 /PRNewswire/ -- China's Zhangshu City, a famed industrial hub of traditional Chinese medicine (TCM) for centuries, has actively promoted integration of tradition and innovation forChina's traditional medicines and medical treatment on its annual TCM fair.

2025-10-28 16:31 913

Samsung Biologics reports third quarter 2025 financial results

* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...

2025-10-28 14:50 1387

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC

SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or...

2025-10-28 09:46 1016

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...

2025-10-27 22:46 1037

Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion o...

2025-10-27 21:00 963

BioDlink Completes First International Shipment of Bevacizumab to Colombia

* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...

2025-10-27 20:30 1045

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S.  * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...

2025-10-27 19:00 1056

Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials

SINGAPORE, Oct. 27, 2025 /PRNewswire/ -- Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, mar...

2025-10-27 13:22 1277

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL

2025-10-27 11:23 1903

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer

SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...

2025-10-27 09:51 1050

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...

2025-10-27 09:00 1264

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...

2025-10-27 08:00 1188
1 ... 13141516171819 ... 339